In This Article:
-
Revenue: EUR68.8 million, a 6.2% increase from Q2 2023.
-
Gross Margin: 57%, stable compared to Q2 2023.
-
Adjusted EBITDA: EUR9.2 million, 13.4% margin, up from EUR4.8 million in Q2 2023.
-
Net Profit: EUR3.9 million, EUR0.07 per share.
-
Net Cash Position: EUR67.5 million, an increase of EUR4.3 million from the beginning of the year.
-
Medical Segment Revenue Growth: 13% increase, driven by medical devices and services.
-
Software Segment Revenue Growth: 2% increase, with 5% growth in recurring revenue.
-
Manufacturing Segment Revenue Growth: 2% increase, with strong growth in aerospace and MedTech.
-
Cash Flow from Operating Activities: EUR8.4 million.
-
Capital Expenditures: EUR8.5 million, mainly for new plant investments.
Release Date: July 31, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Materialise NV (NASDAQ:MTLS) achieved record quarterly revenue of EUR68.8 million, marking a growth of over 6% compared to Q2 2023.
-
The company reported a gross margin of 57%, consistent with the previous year, indicating stable profitability.
-
Materialise NV (NASDAQ:MTLS) increased its adjusted EBITDA to EUR3.9 million, representing 5.6% of revenue, despite intensified R&D investments.
-
The acquisition of FEops is expected to create growth opportunities in the medical segment, particularly in the cardiovascular market.
-
Materialise NV (NASDAQ:MTLS) formed a strategic partnership with nTop, enhancing its ability to process complex 3D printing designs efficiently.
Negative Points
-
The prototyping market continues to show structural weakness, which may impact future growth in the manufacturing segment.
-
The integration of FEops is expected to have a limited negative impact on EBIT initially due to integration costs and further investments.
-
Despite growth, the software segment's adjusted EBITDA margin decreased due to intensified R&D efforts.
-
The manufacturing segment faces challenges from continued low prototyping demand, affecting overall growth potential.
-
High capital expenditures, particularly in the new ACTech plant, are impacting free cash flow, keeping it close to breakeven.
Q & A Highlights
Q: Can you provide more details on the financial impact of the FEops acquisition? A: Koen Berges, CFO, explained that the acquisition will not materially impact the net cash position. However, it will require further cash outflows to support FEops' growth, including R&D investments and working capital needs. The integration will initially have a limited negative impact on EBIT, expected to decrease over time as revenue grows and cost synergies are implemented.